6-(furan-2-yl)-3-aminopyridine | 898289-46-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(furan-2-yl)-3-aminopyridine
• 英文别名: 6-(furan-2-yl)pyridin-3-amine；6-(furan-2-yl)pyridin-3-ylamine；6-(2-furanyl)pyridin-3-amine
• CAS: 898289-46-8
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: VNMHMTVDBPWALF-UHFFFAOYSA-N

物化性质

• 沸点：
  312.9±27.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  对羧基苯磺酰胺 、 6-(furan-2-yl)-3-aminopyridine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.25h， 以78%的产率得到N-[6-(2-furanyl)pyridin-3-yl]-4-sulfamoylbenzamide
  参考文献：
  名称：

  Structure-Based Ligand Design of Novel Bacterial RNA Polymerase Inhibitors

  摘要：

  Bacterial RNA polymerase (RNAP) is essential for transcription and is an antibacterial target for small molecule inhibitors. The binding region of myxopyronin B (MyxB), a bacterial RNAP inhibitor, offers the possibility of new inhibitor design. The molecular design program SPROUT has been used in conjunction with the X-ray cocrystal structure of Thermus thermophilus RNAP with MyxB to design novel inhibitors based on a substituted pyridyl-benzamide scaffold. A series of molecules, with molecular masses <350 Da, have been prepared using a simple synthetic approach. A number of these compounds inhibited Escherichia coli RNAP.

  DOI：

  10.1021/ml200087m
• 作为产物：
  描述：

  2-羟基-5-硝基吡啶 在 四(三苯基膦)钯 、 铁粉 、 sodium carbonate 、 溶剂黄146 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 19.0h， 生成 6-(furan-2-yl)-3-aminopyridine
  参考文献：
  名称：

  Structure-Based Ligand Design of Novel Bacterial RNA Polymerase Inhibitors

  摘要：

  Bacterial RNA polymerase (RNAP) is essential for transcription and is an antibacterial target for small molecule inhibitors. The binding region of myxopyronin B (MyxB), a bacterial RNAP inhibitor, offers the possibility of new inhibitor design. The molecular design program SPROUT has been used in conjunction with the X-ray cocrystal structure of Thermus thermophilus RNAP with MyxB to design novel inhibitors based on a substituted pyridyl-benzamide scaffold. A series of molecules, with molecular masses <350 Da, have been prepared using a simple synthetic approach. A number of these compounds inhibited Escherichia coli RNAP.

  DOI：

  10.1021/ml200087m

文献信息

• [EN] SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZO[1,5-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2016073889A1

  公开（公告）日：2016-05-12

  The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidine compounds described herein include substituted 2,4-dimethyl-N-phenylimidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.

  这项发明提供了取代的咪唑并[1,5-a]嘧啶和相关的有机化合物，包含这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗患者的医疗疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症。本文描述的示例取代的咪唑并[1,5-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基咪唑并[1,5-a]嘧啶-8-羧酰胺化合物及其变体。
• A General Method for Suzuki–Miyaura Coupling Reactions Using Lithium Triisopropyl Borates
  作者：Matthias A. Oberli、Stephen L. Buchwald

  DOI：10.1021/ol302063g

  日期：2012.9.7

  Conditions for the Suzuki–Miyaura coupling of lithium triisopropyl borates are reported, as well as a procedure for a one-pot lithiation, borylation, and subsequent Suzuki–Miyaura coupling of various heterocycles with aryl halides. These borate species are much more stable toward protodeboronation than the corresponding boronic acids and can conveniently be stored on benchtop at room temperature.

  报道了三异丙基硼酸锂 Suzuki-Miyaura 偶联的条件，以及各种杂环与芳基卤化物的单锅锂化、硼酸化和随后的 Suzuki-Miyaura 偶联的程序。这些硼酸盐比相应的硼酸对原脱硼更稳定，可以方便地在室温下储存在台式上。
• Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders
  申请人：Lysosomal Therapeutics Inc.

  公开号：US10786508B2

  公开（公告）日：2020-09-29

  The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidine compounds described herein include substituted 2,4-dimethyl-N-phenylimidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.

  本发明提供了取代的咪唑并[1,5-a]嘧啶及相关有机化合物、含有此类化合物的组合物、医用试剂盒以及使用此类化合物和组合物治疗患者的内科疾病（如戈谢病、帕金森病、路易体病、痴呆症或多系统萎缩）的方法。 本文所述的示例性取代咪唑并[1,5-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基咪唑并[1,5-a]嘧啶-8-甲酰胺化合物及其变体。
• Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity
  作者：Eva Řezníčková、Tomáš Gucký、Veronika Kováčová、Haresh Ajani、Radek Jorda、Vladimír Kryštof

  DOI：10.1016/j.ejmech.2019.111663

  日期：2019.11

  Receptor tyrosine kinase PDGFR alpha is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFR alpha and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFR alpha and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFR alpha and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFR alpha signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia. (C) 2019 Elsevier Masson SAS. All rights reserved.
• SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  申请人：Lysosomal Therapeutics Inc.

  公开号：EP3215510A1

  公开（公告）日：2017-09-13